Dr. Reddy’s announces the launch of Sirolimus tables in US

Renowned pharmaceutical company, Dr. Reddy’s Laboratories has announced the launch of Sirolimus Tablets in the US market. The company has launched this therapeutic equivalent generic version of RAPAMUNE® or Sirolimus tablets, after the approval by the United States Food & Drug Administration (USFDA).

According to IMS Health, the RAPAMUNE® tablets had US sales of about $206 million MAT for the most recent twelve months ending in August 2014.

Dr. Reddy’s Sirolimus tablets in 1 mg and 2 mg are available in bottle counts of 100, shared the company.

A generic version of Wyeth's Rapamune tablets, an immunosuppressant, is advised to be used by only physicians experienced in immunosuppressive therapy and management of renal transplant patients should use sirolimus.

Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient, said the company.